- cafead   Feb 24, 2023 at 09:12: AM
via Novartis has abandoned its ex vivo sickle cell disease (SCD) program developed using Intellia Therapeutics’ CRISPR gene editing platform, according to Intellia's 2022 financial results released Thursday.
article source
article source